$HIMS, the stock for Hims & Hers Health Inc., experienced a significant decline, dropping nearly 10% after hours, including a 9% drop initially. This drop follows investor concerns about the company's future revenue streams and its plans to offer tirzepatide, a weight-loss drug, later this year. The company currently offers compounded semaglutides and is expected to add tirzepatide to its offerings. Meanwhile, the FDA has clarified policies for compounders as the national supply of GLP-1 drugs, including tirzepatide, begins to stabilize. Despite the selloff, some investors are taking advantage of the lower stock prices, with early buyers purchasing 5000 February $20 calls at $2.20. The retail crowd appears to be in shambles over the performance anxiety.